Intravenous bisphosphonates for postmenopausal osteoporosis

Abstract

• Abstract
• Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the suboptimal therapeutic compliance in postmenopausal women, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women .These preparations would become an option for patients who can not tolerate oral BPs or it was ineffective in increasing their bone density.
• This article proposed to review effectiveness and tolerability of intravenous BPs in postmenopausal women with osteoporosis.
• KEYWORDS: Bisphosphonates, Postmenopausal, Osteoporosis, Pamidronate, Ibandronate, Zoledronic Acid.